BeiGene, Ltd. (BGNE)

164,44 +3,88 (+2,42%) Alla chiusura: 04:00PM EDT

BeiGene, Ltd.

94 Solaris Avenue
Camana Bay KY1-1108
Cayman Islands
345-949-4123
https://www.beigene.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 10.600

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. John V. Oyler	Co-Founder, Executive Chairman & CEO	2,43M	N/D	1968
Dr. Xiaobin Wu Ph.D.	President & COO	1,7M	N/D	1962
Dr. Xiaodong Wang Ph.D.	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder	4,42M	N/D	1963
Ms. Julia Wang	CFO & Principal Financial Officer	1,07M	N/D	1971
Mr. Chan Lee	General Counsel & Senior VP	1,01M	N/D	1968
Mr. Wang Lai Ph.D.	Global Head of R&D	1,12M	N/D	1977
Mr. Titus B. Ball	VP & Chief Accounting Officer	N/D	N/D	1973
Ms. Liza Heapes	Head of Investor Relations	N/D	N/D	N/D
Mr. Yang Ji	Chief Compliance Officer	N/D	N/D	N/D
Dr. Yan Qi	Senior VP & Head of Public Affairs - Greater China	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

BeiGene Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Governance aziendale

L'ISS Governance QualityScore di BeiGene, Ltd. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 5; diritti degli azionisti: 6; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.